Review
Evidence for Utilization of Injectable Biologic
Augmentation in Primary Rotator Cuff Repair
A Systematic Review of Data From 2010 to 2022
Olivia J. Bono,*† BA, Bryan Jenkin,‡ BA, Julianne Forlizzi,§ MD, Albert Mousad,‡ BA,
Stephen Le Breton,‡ BA, Meghan MacAskill,§ MS, Krishna Mandalia,‡ BA, Kai Mithoefer,§ MD,
Arun Ramappa,k MD, Glen Ross,§ MD, and Sarav S. Shah,§ MD
Investigation performed at New England Baptist Hospital, Boston, Massachusetts, USA
Background: Biologic healing after rotator cuff repair remains a significant challenge. Injectable biologic augmentation may
improvetissuequalityatthesuture-tendoninterface.
Purpose: To investigate the effect of injectable biologic supplementation in rotator cuff repair and to assess the quality and
adherencetoevolvingreportingstandards.
StudyDesign:Systematicreview;Levelofevidence,3.
Methods:AsystematicreviewwasconductedfollowingPRISMA(PreferredReportingItemsforSystematicReviewsandMeta-
Analyses) guidelines. Included were 40 studies: 29 preclinical (in vivo animal models) and 11 clinical. Each clinical study was
assessed for quality, risk of bias, and adherence to relevant MIBO (Minimum Information for Studies Evaluating Biologics in
Orthopaedics)guidelines.Theoutcomesofinterestwerereportedloadtofailure,loadtogap,gapsize,andstiffnessinthepre-
clinicalstudies,andhealingrateandanypatient-reportedoutcomemeasuresintheclinicalstudies.
Results: Injectables reported included growth factors (eg, transforming growth factor–beta 3, erythropoietin), bone marrow–
derivedmesenchymalstemcellsandadipose-derivedmesenchymalstemcells(ADSCs),andotheragentssuchasplatelet-rich
plasma (PRP) and hyaluronic acid. The most common findings for preclinical injectables were increased load to failure (16/29
studies;55.2%)andimprovedcollagenhistologicalquality(11/29studies;37.9%).All11clinicalstudies(10PRP,1ADSC)indi-
catednoadverseevents,withsimilarorimprovedpatient-reportedoutcomescomparedwithrepairsinthecontrolgroups.In1
study utilizing an innovative delivery technique, a concentrated PRP globule with fibrin matrix was shuttled over a suture to
maintainconcentratedPRPattherepairsiteanddemonstratedasignificantdecreaseinretears(P¼.03)ata31-monthfollow-up.
A matched-cohort study investigating augmentation with ADSCs demonstrated a significantly lower retear rate in the ADSC-
augmented group than the control group at a 28-month follow-up (P < .001). On average, the clinical studies adhered to 66%
ofrelevantMIBOreportingguidelinesandhadalowriskofbias.
Conclusion: Approximately 83% of preclinical studies found a positive biomechanical or histological effect, with no studies
showing an overall negative effect. Clinically, utilization of innovative delivery techniques may reduce the risk of arthroscopic
washoutofPRPandimproveretearrates.ADSCswereshowntoreduceretearratesata28-monthfollow-up.
Keywords:rotatorcuffrepair;augmentation;injectablebiologics;platelet-richplasma
Rotator cuff tears (RCTs) are a significant source of mor- United States ages and remains physically active. Day
bidity, often causing pain, loss of function, and difficulty et al5 demonstrated that the frequency of RCRs has
with activities of daily living. Surgical management of increasedby188%between2007and2015.Therecontinues
RCTsviarotatorcuffrepair(RCR)isoftenindicatedafter to be a wide discrepancy in retear rates despite improve-
failed nonoperative management given the potential to ment in surgical techniques, with retear rates varying
improve symptoms and function. The disease burden of between11%and94%dependingontearsize.14,36Mechan-
RCTs has increased as the average population in the ical failure of the RCR is most common within the 3 to 4
monthsaftertheinitialrepair.26,45Earlypostoperativefail-
ures suggest that biologic tendon healing may be slower
TheOrthopaedicJournalofSportsMedicine,11(2),23259671221150037
thanpredicted,andthatslowtendonhealingmaybelinked
DOI:10.1177/23259671221150037
ªTheAuthor(s)2023 toafailedhealingresponseanddecreasedvascularity.30It
Thisopen-accessarticleispublishedanddistributedundertheCreativeCommonsAttribution-NonCommercial-NoDerivativesLicense(https://creativecommons.org/
licenses/by-nc-nd/4.0/),whichpermitsthenoncommercialuse,distribution,andreproductionofthearticleinanymedium,providedtheoriginalauthorandsourceare
credited.Youmaynotalter,transform,orbuilduponthisarticlewithoutthepermissionoftheAuthor(s).Forarticlereuseguidelines,pleasevisitSAGE’swebsiteat
http://www.sagepub.com/journals-permissions.
1

NEW PAGE

2 Bonoetal TheOrthopaedicJournalofSportsMedicine
has been shown that a subpar anabolic response is more Administration has created expedited pathways to help
commonaspreoperativetearsizeincreases.44FailedRCR support the exploration and utilization of regenerative
canleadtoalteredglenohumeraljointkinematicsresulting products, including injectable biologics.63 This has
in superior humeral translation, articular wear, and ulti- sparkedanimprovedunderstandingandimplementation
matelycuffteararthropathy.Giventheassociationoffailed ofthetechnologies.
healingresponseanddecreasedvascularitywithincreased The purpose of this study was to both investigate the
retearrate,methodstostimulatethebiologicalmilieuare effect of injectable biologic supplementation in RCR and
crucialtodecreasethemorbidityofearlyRCRretears.16 assess the quality and adherence to evolving reporting
Novel suture materials and anchors, in combination standards.
with new surgical techniques such as the double-row
transosseous equivalent repair, have enhanced the
time-zeromechanicalstrengthofRCRs.4,62However,the METHODS
suture-tendon interface of the RCR continues to have
AsystematicreviewwasperformedusingPRISMA(Pre-
the greatest susceptibility to failure.51 A consequence of
ferred Reporting Items for Systematic Reviews and
poor tissue quality at the suture-tendon interface is
Meta-Analyses) guidelines.46 The search utilized the
suture pullout and eventual retear. Biologic healing
PubMedcentraldatabaseinJanuary2022.Twoindepen-
remainsasignificantchallengeastendontearrecurrence
dent researchers performed the search, with the senior
is associated with clinical deterioration in the long-term
author mediating any disputes. Broad augmentation
period.28,66 Injectable biologic augmentation has been
searchtermswereinitiallyused.Thesearchtermsused
hypothesized to improve tissue quality at the suture-
were ((((microfracture) OR (vented anchors)) OR (plate-
tendoninterface.
let rich plasma)) OR (amnion)) OR (adipose tissue)) OR
In an effort to improve biological healing, various ana-
(bonemarrowaspirationconcentrate))OR(nandrolone))
bolicpathwayshavebeentargetedusingavarietyofinject-
OR(augmentation))OR(biologics))OR(growthfactors))
ables such as growth factors, platelet-rich plasma (PRP),
OR(genetherapy))OR(stemcells))OR(tissueengineer-
and bone marrow–derived mesenchymal stem cells
ing)) AND (((rotator cuff repair) OR (single-row repair))
(BMSCs) or adipose-derived mesenchymal stem cells
OR (double-row repair)) with filters as follows: date
(ADSCs).Growthfactorssuchastransforminggrowthfac-
range of January 1, 2010, to January 1, 2022; English
tor–beta(TGF-b)havebeenshowntopromotetenocytedif- language.
ferentiationandimprovecollagenproduction.58PRPisan The initialsearchresultedin1159 titles,to which the
amalgamationofgrowthfactorsandimmunomodulatorsto following criteria were applied. Inclusion criteria were
ultimately accelerate tissue regeneration.43 Mesenchymal titles that specified RCR and augmentation techniques
stemcellsalsoutilizegrowthfactorparacrinesignalingto in peer-reviewed journals. The exclusion criteria were
improve wound healing and tissue quality. Additionally, reviewarticles,systematicreviews,editorials,technique
stem cells may differentiate into the damaged tissue to articles, those without reported patient outcomes or the
improve the biologic microenvironment and promote appointed outcome surrogates, case reports, and articles
healing.13 focused on superior capsular reconstruction/not focused
Biologicinjectableshavebeenusedinthetreatmentof onRCR.Theabstractsofthearticleswerethenreviewed,
a variety of orthopaedic pathologies, including osteoar- excluding duplicates and articles that were case series
thritis, tendinopathies, degenerative disk disease, and with <15 patients; review articles not previously elimi-
fractures.32Biologicsstimulatethereleaseofgrowthfac- nated;articlesnotrelatedtoRCR;studiesfocusedonaug-
tor and anti-inflammatory cytokines in order to promote mentation that did not fall within the 3 categories of
healing,improvetissuequality,andalleviatesymptoms. injectable,marrowstimulation,orgraft/scaffoldaugmen-
Thereisconsiderablevariabilityinthetypesofbiologics tation;clinicalstudieswithaminimumaveragefollow-up
andtheirpreparations(eg,hydrogels,salinesuspensions, of <24 months; or those without abstract for review.
and electrospun matrixes), as well as the reporting of Therewasnominimumfollow-uptimeforthepreclinical
processing details.37 The United States Food and Drug studies.Thisprocesseliminated968articles,leaving191
*AddresscorrespondencetoOliviaJ.Bono,BA,AlbanyMedicalCollege,49NewScotlandAvenue,Albany,NY12208,USA(email:oliviabono@gmail.
com).
†AlbanyMedicalCollege,Albany,NewYork,USA.
‡TuftsUniversitySchoolofMedicine,Boston,Massachusetts,USA.
§NewEnglandBaptistHospital,Boston,Massachusetts,USA.
kBethIsraelDeaconessMedicalCenter,Boston,Massachusetts,USA.
FinalrevisionsubmittedSeptember12,2022;acceptedOctober21,2022.
Oneormoreoftheauthorshasdeclaredthefollowingpotentialconflictofinterestorsourceoffunding:J.F.hasreceivedgrantsupportfromArthrex,
educationpaymentsfromKairosSurgicalandSmith&Nephew,andhospitalitypaymentsfromStryker.K.M.hasreceivedconsultingfeesandhonorariafrom
Vericel.A.R.hasreceivededucationpaymentsfromArthrex.G.R.hasreceivededucationpaymentsfromKairosSurgical,consultingfeesfromStryker,and
hospitalitypaymentsfromArthrexandWrightMedical.S.S.S.hasreceivededucationpaymentsfromArthrexandconsultingfeesfromExactech.AOSSM
checksauthordisclosuresagainsttheOpenPaymentsDatabase(OPD).AOSSMhasnotconductedanindependentinvestigationontheOPDanddisclaims
anyliabilityorresponsibilityrelatingthereto.

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 3
forfull-textreview.Full-textinclusioncriteriawereclin- studies with in vivo animal models and clearly reported
ical studies with a clearly reported healing rate or any load to failure, load to gap, gap size, or stiffness.
patient-reported outcome measure, and preclinical Anyremainingstudiesthatwerenotfocusedoninjectable
augmentationwereexcluded.Basedonthiscriterion,151
studieswereremoved.Thefull-textreviewresultedinthe
inclusion of 40 studies (11 clinical and 29 preclinical).
AflowchartofsearchmethodologyisshowninFigure1.
Secondaryreviewoftheclinicalstudiesincludedassess-
ment of adherence to MIBO (Minimum Information for
Studies Evaluating Biologics in Orthopaedics) guidelines
and assessment of study quality and risk of bias.37 The
methodologic quality of the included primary studies was
evaluated using the Cochrane risk-of-bias tool24 for ran-
domized controlled trials andthe Newcastle-Ottawa Scale
(NOS)71fornonrandomizedstudies.TheNOSassessesthe
risk of bias in observational studies by employing 7 ques-
tionsacross3domains:selectionofparticipants,compara-
bility among studied groups, and outcomes assessment.
Thestudieswerethenfurthercategorizedashavingpoor,
fair, orgoodqualityviarecommendation fromthe Agency
for Healthcare Research and Quality, dependent on each
study’sNOSorCochranerisk-of-biastoolscores.Appendix
Tables 1 and 2 demonstrate the score determinations for
Figure1.PRISMA(PreferredReportingItemsforSystematic
each included study according to the Cochrane risk-of-
ReviewsandMeta-Analyses)flowchartofthestudyinclusion
biastoolandtheNOS,respectively.
process.RCR,rotatorcuffrepair.
TABLE1
GrowthFactorsinPreclinicalStudiesa
Specific FirstAuthor Animal
Augment (Year) MethodofDelivery Model Follow-up NetEffect RepresentativeFindings
TGF-b3þ Rothrauff Fibrinorgelatin Rat 4,8wk Inconclusive Nodifferencesinloadtofailureorstiffness
ADSC (2019)57 methacrylate comparedwithcontrolgroup
hydrogels
TGF-b3 Reifenrath Electrospun Rat 4,8wk Positive Similarmaximumforcevaluestonativetendon
(2020)54 chitosan-coated (P(cid:2).01)
polycaprolactone
fiberscaffolds
TGF-b3 Han(2020)21 Tendonspecificcross- Rat 4,6wk Positive Collagenorganizationandcellulararrangement
linkedgelatin wasmoreorganized;perforatingfiberswere
observed;morefibrocartilageatinsertions
TGF-b1 Arimura Gelatinhydrogel Rat 6,12wk Positive Significantlyhigherultimateloadtofailure(P¼
(2017)1 .002)andhighercollagencontent(P¼.001)at
12wk
FGF-2 Yonemitsu Soakedgelatin Rat 2,6,12 Positive Ultimateloadtofailure,stiffness,andultimate
(2019)72 hydrogels wk stresstofailureoftherepairsitewerehigherin
FGF-2groupcomparedwithcontrolgroup(P<
.05);alsoshowedsignificantlyhigher
histologicalscores(P<.05)
FGF-2 Tokunaga Soakedgelatin Rabbit 2,6wk Positive Significantlyhigherultimateloadtofailureand
(2017)60 hydrogels stresstofailurecomparedwithcontrolgroupat
6wk(P<.05)
G-CSF Buchmann Gelatinhydrogel Rat 3,6wk Positive Significantlyhigherloadtofailureratio(P¼.02);
(2015)3 significantlyhighercollagen3contentand1/3
ratio
Erythropoietin Oztermeli None Rat 10,28d Inconclusive Nosignificantbiomechanicalandhistological
(2019)48 differenceswhencomparedwiththecontrol
aADSC,adipose-derivedmesenchymalstemcell;FGF-2,fibroblastgrowthfactor2;G-CSF,granulocytecolony-stimulatingfactor;TGF-b1,
transforminggrowthfactor–beta1;TGF-b3,transforminggrowthfactor–beta2.

NEW PAGE

4 Bonoetal TheOrthopaedicJournalofSportsMedicine
TABLE2
BMSCs,ADSCs,andDerivativesinPreclinicalStudiesa
FirstAuthor Methodof Animal Follow- Representative
SpecificAugment (Year) Delivery Model up NetEffect ProcessingDetails Findings
Allogeneic Gu¨lec¸yu¨z Saline Rat 8wk Positive Harvestedratbone Nosignificantincreasein
BMSC (2018)17 marrowwas meanmusclemass;
centrifugedandthen significantlylessfattening
suspendedinan (P<.001)
inductionmediumand
transfectedwithgreen
fluorescentprotein
beforebeingincubated
withmyocytes
Human Dyrna(2018)9 Fibringel Mouse 8wk Positive Subacromialbursaltissue Humansubacromialbursal
subacromial harvestedfromhuman cellshaveasignificantly
bursalcellsvs rotatorcuff;bone highernumberofcells
bonemarrow marrowaspirate infiltratingandmorecells
stromalcells collectedfromhuman overallcomparedwith
proximalhumeral bonemarrowstromalcells;
head;bothsamples increasedhealingtissue
wereexpandedin bridge(P<.05)
culture
BMAC Liu(2018)39 BMAC Rabbit 6wk Positive Bonemarrowaspirate Significantlyhigherultimate
solution harvestedfromrabbits; loadtofailureandstiffness
singlecentrifugation; intheBMACrepairgroup
point-of-careinjection comparedwithsaline
repairandPRPrepair
groups(P<.05);inthein
vitromodel,BMAC-
treatedgroupsshowed
bettercollagen
arrangement
BMSCisolated Degen(2016)6 Fibringlue Rat 2,4wk Inconclusive Acquiredsingle-donor Earlyincreaseinloadto
frombone commerciallyavailable failureandstiffness(P¼
marrow BMSCs;expandedin .002and<.0001)butbywk
aspiration culture 4therewerenosignificant
differences;increased
fibrocartilagepresentat2
wk(P¼.026)
Adiposestromal Lu(2018)41 Fibringel Rabbit 8wk Positive Harvestedrabbitadipose Increasedloadtofailure,
vascular tissuetoobtainstromal stiffness,andtendon-bone
fraction- vascularfraction maturityscores(P<.01);
containing suspension;point-of- higherexpressionlevelof
stemcells careinjection collagen1,BMP-2,and
quantifiedamountof
BMP-2comparedwith
controlgroup(P¼.006)
Adiposestromal Lu(2018)40 Fibringel Rabbit 12wk Positive Harvestedrabbitadipose Increasedloadtofailure,
vascular tissuetoobtainstromal stiffness,andstrength(P
fraction- vascularfraction <.01forall)
containing suspension;point-of-
stemcells careinjection
Adiposestem Wang(2020)68 Phosphate- Rabbit 18wk Positive Isolatedfromhuman Significantlylowerfatty
cell–derived buffered subcutaneousadipose infiltration(P<.001),
exosomes saline tissuecollectedfrom higherstiffness,higher
liposuctionsurgery; histologicalscore,and
point-of-careinjection morenewlyregenerated
fibrocartilageatrepairsite
ADSC Kim(2017)29 Acellular Rabbit 8wk Positive Isolatedfromhuman Ledtomorematuretendons
dermal wasteadiposetissue withcellularinfiltration
matrix fromelectivesurgery; intothegraftandevidence
expandedinculture ofneotendonformation
comparedwithcontrol
group
(continued)

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 5
Table2(continued)
FirstAuthor Methodof Animal Follow- Representative
SpecificAugment (Year) Delivery Model up NetEffect ProcessingDetails Findings
Human Wang(2019)69 Saline, Rat 16wk Positive Humansubcutaneous Betterbiomechanical
subcutaneous lactated adiposetissuecollected propertiesanddecreased
adiposetissue ringers fromliposuction atrophyandfatty
surgery;expandedin infiltrationcomparedwith
culture controlgroup(P<.001)
Human Gumucio Saline, Rat 2wk Positive Collectedfromcosmetic 40%reductionin
subcutaneous (2016)18 lactated procedure;point-of- hydroxyprolinecontent
adiposetissue ringers careinjection comparedwithcontrol
group
aADSC,adipose-derivedmesenchymalstemcell;BMAC,bonemarrowaspirateconcentrate;BMP-2,bonemorphogeneticprotein2;BMSC,
bonemarrow–derivedmesenchymalstemcell.
RESULTS fatty infiltration (P < .001), and more newly regenerated
fibrocartilage atthe repair sitecompared with the control
Preclinical Studies group. Overall, stem cell–based biologics both were the
mostcommonlyusedanddemonstratedthemostpromising
Twenty-ninepreclinicalstudies{relatedtoinjectablebiolo-
results,suchasincreasedloadtofailure,stiffness,andcel-
gics were identified. There were 16 studies# (55%) per- lularinfiltration.
formed in a rat model, 11 studies** (38%) conducted in Awiderangeofotherinjectableshavebeeninvestigated,
rabbits,and2studies9,70(7%)conductedinmice.Notably, including melatonin, hyaluronic acid, and recombinant
no injectable was found to have a negative effect on out- humanparathyroidhormone(Table3).Gurgeretal19dem-
comesinthepreclinicalsetting. onstrated that PRP augmentation can be supplemented
Avarietyofgrowthfactors(Table1)wereinvestigatedin withgaseousozonetoimprovebothbiomechanicalandhis-
the preclinical setting, with 4 of the 8 studies involving topathological findings in a rat RCR model. The combina-
TGF-bsubtypes.Allgrowthfactors,excepterythropoietin, tionofPRPandozonegaswasshowntobeamoreeffective
were delivered in a gel/scaffold. There was a significant interventionthaneitherPRPorozonealone.19Kwonetal34
increaseinloadtofailureforallgrowthfactorswhencom- determinedthatRCRaugmentationwithhumanumbilical
pared with the control group (P < .05), except TGF-b3 þ stem cells improved functional outcomes (eg, walking dis-
ADSC and erythropoietin.48,57 Interestingly, Reifenrath tance,walkingspeed)inrabbits.Ofnote,thiswastheonly
et al54 found that TGF-b3 alone led to a load to failure preclinical study that investigated functional outcomes in
similartonativetissueintheirratmodel.Anothergrowth ananimalmodel.
factor investigated that has had positive results is granu- Overall,increasedloadtofailurewasthemostcommon
locyte colony-stimulating factor (G-CSF). Buchmann and biomechanical improvement, with 55.2% of all preclinical
colleagues3 found that sustained release of G-CSF from injectables demonstrating this finding. Histologically,
vesicularphospholipidgelsresultedinnotonlyhigherload 37.9%ofthestudiesdemonstratedimprovedcollagenqual-
tofailure(P¼.02),butalsoasignificantlyhighercollagen3 ity and/or quantity with the use of injectables. Notably,
contentandcollagen1/3ratio(P<.05). none of the BMSCs provided lasting collagenous improve-
BMSCs and ADSCs demonstrated both histological and ments. Five substances (botulinum toxin A, recombinant
mechanical benefits, including greater load to failure and humanparathyroidhormone,TGF-b3þADSC,andBMSC
reduced fatty infiltration (Table 2). Common methods of frombonemarrowaspiration)didnotdemonstrateanysig-
delivery include gel and saline suspensions. Liu et al39 nificantimprovementinoutcomesbetweenthecontroland
investigated the application of bone marrow aspirate con- interventiongroups.6,7,15,57
centrate (BMAC) after RCR in a rat model and demon-
strated that the addition of BMAC resulted in Clinical Studies
significantly higher stiffness and loadtofailure compared
Eleven clinical studies (10 PRP,†† 1 ADSC31) were identi-
withthecontrolgroup(P<.05),aswellasbettercollagen
fiedintotal(Table4).Clinicalexplorationofinjectablebio-
at the tendon-bone interface. Using a rabbit model, Wang
et al68 showed that adipose stem cell–derived exosomes logics in RCR has focused on 2 derivatives, PRP and
ADSCs.Intraoperativeimagesdemonstratingtheinjection
deliveredviaphosphate-bufferedsolutionresultinsignifi-
ofabiologicaugmentintothesiteofRCRaredisplayedin
cantly higher stiffness and load to failure (P < .05),lower
Figure2.Analysisofriskofbiasandreportingofrelevant
MIBO guidelines were performed and the results are
{References1,3,6,7,9,15,17–19,21,22,25,29,34,35,39–41,47, shown in Figure 3. The studies were found to have a low
48,54,55,57,59,60,68–70,72.
#References1,3,6,7,15,17,18,21,22,47,48,54,57,59,69,72.
**References19,25,29,34,35,39–41,55,60,68. ††References2,8,12,20,38,42,49,52,53,67.

NEW PAGE

6 Bonoetal TheOrthopaedicJournalofSportsMedicine
TABLE3
OtherBiologicInjectablesinPreclinicalStudiesa
SpecificAugment FirstAuthor(Year) MethodofDelivery AnimalModel Follow-up NetEffect RepresentativeFindings
Melatonin Song(2019)59 Melatonin-loaded Rat 2,4,8wk Positive Higherloadtofailure,stress,
aligned andstiffness
polycaprolactone
electrospunfiber
Humanumbilical Kwon(2018)34 Mixedwith Rabbit 6wk Positive Newlyregeneratedcollagen
cordstemcell hyaluronicacid type1fibers;cell
orpolydeoxy- proliferation,
ribonucleotide angiogenesis,walking
injection distance,fastwalking
time,andmeanwalking
speedweregreater
Kartogenin Wang(2018)70 Fibrinsealant Mouse 2,4wk Positive Highermeanloadtofailure
(P¼.04)withsuperior
collagenfiberorganization
(P<.01);lesspercentage
areaoffibrocartilage
(P¼.04)
Allogenicdermal Kwon(2018)35 Fibrin Rabbit 6wk Positive Meanloadtofailure
fibroblasts significantlyhigher(P¼
.011);greatercollagen
fibercontinuity
Hyaluronicacid Honda(2017)25 Nosuspension Rabbit 4,8,12wk Positive Nodifferenceinloadto
failure;significantlymore
CD44-positivecells,more
cartilaginouspellet
produced,increased
expressionoftype2
collagen,SOX9,and
aggrecan
Poly-N-acetyl Nuss(2017)47 Nosuspension Rat 2,4,8wk Positive Significantlyincreasedload
glucosamine tofailureat4wk;no
histologicaldifferences
Humanrotator Harada(2017)22 Cellsheet Rat 4,8wk Positive Significantlyhigherloadto
cuffcells failure
ADFs Rhee(2021)55 Fibrinsuspension Rabbit 4,6,12wk Positive Higherloadtofailure,
collagencontinuity,
orientation,and
maturationofthetendon-
bonejunctionwerebetter
intheADFþfibrin
interventionwhen
comparedwithPRP
Ozone(O O )þ Gurger(2021)19 None Rabbit 6wk Positive Higherloadtofailureand
2 3
PRP bettercollagen
histopathologyinthe
ozone,PRP,andozoneþ
PRPgroups;ozonealone
wasfoundtohavebetter
histologicalproperties
thanthePRPgroup
BotulinumtoxinA Gilotra(2016)15 Nosuspension Rat 4,12wk Inconclusive At4wk,increasedloadto
failure;morelinear
formationofcollagen
comparedwiththesaline
controlgroup
Recombinant Duchman(2016)7 Nosuspension Rat 12,16wk Inconclusive Significantlyhigherearly
human loadtofailurethan
parathyroid controls(P¼.003);no
hormoneon differenceinloadtofailure
POD7 by16wk
aADF,allogenicdermalfibroblast;PRP,platelet-richplasma;POD7,postoperativeday7.

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 7
TABLE4
InjectableBiologicsinClinicalStudiesa
Percentageof
First MIBO
Specific Author Follow- Postop Processing SignificantFindings Guidelines
Augment (Year) LOE n TearSize up Imaging Details ofInterventionGroup Reported
PRP Malavolta 2 54 Small, 5y MRI Preparedby Nosignificantdifference 76
(2018)42 medium apheresiswith clinically(UCLA,Constant,
additionof VASscores)atanyfollow-up
thrombin (P>.05);nodifferencein
retearratesbetweengroups
(P¼.203).
PRPinfibrin Walsh 2 72 Smallto 2y MRI Leukocytepoor; Nosignificantdifferencein 60
matrix (2018)67 large double retearrate,WORCscore,SST,
centrifugation orshoulderstrengthindex
betweengroups(P>.05)
PRP Gwinner 3 36 <5cm 2y MRI Leukocytepoor; Nosignificantdifference 49
(2016)20 single clinicallyorstructurally
centrifugation
PRP Flury 1 103 Ssponly 2y MRI/US Single Nosignificantdifference 67
(2016)12 centrifugation clinicallyorstructurallyat
finalfollow-up;smokinghad
negativeinfluenceonthePRP
groupclinicallyuntil12-mo
follow-up
Platelet-rich Dukan 3 69 Ssponly 2y MRI Leukocytepoor; Nosignificantdifference 67
fibringel (2019)8 single clinicallyorstructurallyat
centrifugation finalfollow-up,although
improvedConstantandVAS
scoresat3mopostopin
treatmentgroup
PRPfibrin Barber 3 40 <3vs(cid:3)3cm 31mo MRI Leukocytepoor Statisticallysignificantdecrease 62
matrix (2011)2 withdouble inretearsinthePRPgroup(P
centrifugation ¼.03);PROMsdidnotdiffer
betweengroups,exceptRowe
score
PRP Pandey 1 102 Mediumto 2y US Single-spin Significantlylowerretearratein 73
(2016)49 large centrifugation, PRPgroupcomparedwith
leukocytepoor controlgroup(P¼.01)
PRP Randelli 1 53 Minor(stage 2y MRI Double Nosignificantdifferencein 69
(2011)52 1)to centrifugation healingratebetweengroups
massive
(stage4)
PRP Randelli 2 38 Small(C1-2) 10y US Double Goodclinicalresultsinboth 69
(2022)53 tolarge centrifugation groups,butonlysignificant
(C3-4) differenceinASESandSANE
scores;nosignificant
differenceinretearrate
PRP Liu 1;3b 96 (cid:2)2vs>2cm 51.9 MRI Leukocyterich; Decreasedretearrateinoverall 64
(2021)38 mo double PRPgroupcomparedwith
centrifugation controlgrouponlyinthose
withtears>2cm(P¼.040);
nosignificantclinicalor
structuraldifferences
betweenPRP-onlyandPRP-
boostergroups
ADSC Kim 3 70 Mediumto 28mo MRI Harvestedand Significantlylowerretearratein 65
(2017)31 massive cultured1 treatmentgroupcompared
dbefore withcontrolgroup(P<.001);
surgery nodifferenceinclinicalscores
betweengroups
aADSC,adipose-derivedmesenchymalstemcell;ASES,AmericanShoulderandElbowSurgeons;LOE,levelofevidence;MRI,magnetic
resonanceimaging;postop,postoperative;PROM,patient-reportedoutcomemeasure;PRP,platelet-richplasma;SANE,single-assessment
numericevaluation;Ssp,supraspinatus;SST,SimpleShoulderTest;UCLA,UniversityofCalifornia,LosAngeles;US,ultrasound;VAS,
visualanalogscale;WORC,WesternOntarioRotatorCuff.
bThiswasbothalevel-1randomizedcontrolledtrialandalevel-3cohortstudy.

NEW PAGE

8 Bonoetal TheOrthopaedicJournalofSportsMedicine
Figure2.Imagesofintraoperativeinjectionofbiologicaugmentafterrotatorcuffrepair.A:Therotatorcuffrepairsitevisualizedby
arthroscope.B:Needleinsertedintothesiteoftherepair.C:Injectionofthebiologicaugmentviatheneedleatthesiteoftherepair.
riskofbiasperNOSandCochraneassessments.Onaver-
PRP booster. While patients who received any PRP aug-
age,66%oftheMIBOguidelineswereadheredto(Table4).
mentation had a significantly improved retear rate com-
pared with the control group (12.5% vs 29.2%; P ¼ .038),
PRPStudies there werenodifferencesinhealingfailureratesbetween
theintraoperativePRP-onlyandthePRP-boostergroupsat
PRPiscreatedbyrapidlyspinningasampleofapatient’s a1-yearfollow-up(P¼.383).Interestingly,whenseparated
wholebloodinacentrifugetoisolatetheplasma.Indoing intosubgroupsbasedontearsize,onlyinthosewithtears
so,plateletsandothergrowthfactors canbeconcentrated >2 cm was the risk of retear significantly reduced in the
withintheplasma.PRPcanbeinjectedintraoperativelyto overall PRP group compared with the control group (P ¼
augment healing with autologous growth factors such as .04). Additionally, the overall PRP group demonstrated
insulin-like growth factor–1 (IGF-1), TGF-b, epidermal improved VAS pain (P ¼ .016) and VAS satisfaction (P ¼
growth factor (EGF), vascular endothelial growth factor .023)scorescomparedwiththecontrolgroup,yettherewas
(VEGF), and others.10 The process of PRP collection and no difference between intraoperative PRP-only and PRP-
injection is shown in Figure 4. Significant heterogeneity boostergroupsinrangeofmotion,functionaloutcomes,or
existsintheliterature,withmultipletrialsfailingtodem- VASforpainandsatisfactionscoresata2-yearfollow-up.38
onstrate any significant improvement in clinical or radio- Inamatchedcase-controlstudywitha31-monthfollow-
graphic outcomes.12,20,42,67 Dukan et al8 in a comparative up,Barberetal2concentratedaPRPglobuleontoafibrin
cohort study of 69 patients investigated the effect of
matrixandshuttledtheglobuleoverasutureinanattempt
autologousPRPgel,whichpointedtoashort-termclinical
tomaintainconcentratedPRPattherepairsiteovertime.
benefit at 3 months that did not persist until the 2-year
The autologous, leukocyte-poor PRP was prepared with
follow-up. In a randomized controlled trial with 102
doublecentrifugationandcalciumchlorideinaprocessthat
patients,Pandeyetal49demonstratedlowervisualanalog
resulted in a PRP construct that was sutured into the
scale (VAS) pain scores in the PRP group at 1, 3, and 6
repair. There was a statistically significant decrease in
months postoperatively, but not at 12 or 24 months. The
retearsinthePRPgroup(30%vs60%inthecontrolgroup;
PRPgroup demonstratedsignificantly improvedConstant
P¼.03)asseenonMRIevaluation.PROMsdidnotdiffer
andUniversityofCalifornia,LosAngeles(UCLA)scores(P
betweengroupswiththeexceptionoftheRowescorefavor-
¼.001),butnotanimprovedAmericanShoulderandElbow
ingtheinterventiongroup.2
Surgeons(ASES)score(P¼.131),at24monthsinthePRP
Randelli et al52,53 have published both 2- and 10-year
group. The retear rate was significantly lower in the PRP
outcomes of a cohort of patients who had PRP augmenta-
groupforlargetears(P¼.014),butnotformediumtears(P
tionofRCR.ThePRPwascollectedusingdoublecentrifu-
>.05).49TheautologousPRPwascollected,processed,ana-
gation and was delivered at the end of the arthroscopic
lyzed,andstoredthedaybeforethesurgery.
repair in its activated form. At 24 months, patients had
To evaluate the effect of repeated PRP application on
RCR, Gwinner et al20 performed a randomized controlled significantlylowerVASscorescomparedwith3,6,and12
monthspostoperatively.TherewereinitialConstantshoul-
trialof36patientswith2-yearfollow-up,whichcompared
der score benefits 3 and 12 months postoperatively, but
ultrasound-guided injection immediately after the repair
thesebenefitsdidnotpersistatthe2-yearmark.Addition-
and 7 days postoperatively to a control group who did not
receive PRP. All patient-reported outcome measures ally, there was a decrease in retear rates of smaller tears
(PROMs)werestatisticallyinsignificant,andMRIevalua- (grades1and2)comparedwiththecontrolgroupatthe2-
tion of retear rates did not differ between groups at final yearmark.52Atthe10-yearmark,thePRPgrouphadsig-
follow-up(P>.05).20Recently,Liuetal,38ina2-partstudy nificantlyimprovedsingle-assessmentnumericevaluation
consistingofarandomizedcontrolledtrialandcomparative (SANE)andASESscorescomparedwiththecontrolgroup.
cohort study, investigated the effect of administration of However, there was no difference in retear rates or other
PRPintraoperativelyinadditiontoa2-weekpostoperative clinicalassessmentoutcomesata10-yearfollow-up.53

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 9
Figure 3. Heatmap of adherence to MIBO (Minimum Information for Studies Evaluating Biologics in Orthopaedics) reporting
guidelinesfortheclinicalstudiesreviewed.1‡‡

NEW PAGE

10 Bonoetal TheOrthopaedicJournalofSportsMedicine
Figure4.A:Depictionofinjectionofbiologicintothesiteofrotatorcuffrepair.B:Processofplatelet-richplasmacollectionand
injection into the repair site releasing growth factors that stimulate tenocyte differentiation and improve collagen quality and
quantity.EGF,epidermalgrowthfactor;IGF,insulin-likegrowthfactor;TGF-b,transforminggrowthfactor–beta;VEGF,vascular
endothelialgrowthfactor.
ADSC Studies Injectables reported included growth factors (such as
TGF-b3 and erythropoietin), ADSCs, BMSCs, and other
Kimet al31 explored the implantation ofADSCs loaded in agents (namely PRP and hyaluronic acid). Approximately
fibringlueasameansofRCR augmentation. Theadipose 83%ofpreclinicalexperimentsdemonstratedapositivebio-
tissue was harvested 1 day before surgery, and cells were mechanicalorhistologicaleffect.Importantly,therewasno
subsequentlycultured.Ameanof4.46(cid:4)106ADSCswere overallnegativeeffect seenbybiologicinjectable augmen-
isolated and loaded into the fibrin glue scaffold. This tation,demonstratingtheconsiderablepotentialforclinical
matched-cohort study demonstrated that the retear rate researchtranslation.
was significantly lower in the intervention group (14.3%) Amonggrowthfactorsinvestigated,nearlyallshoweda
compared with the control group (28.5%) at a 28-month net positive effect. Inthe preclinical setting, the most fre-
follow-up (P < .001). However, there were no significant quentpositiveeffectwasincreasedultimateloadtofailure.
differencesinrangeofmotionorpatient-reportedoutcomes TGF-b1andTGF-b3currentlyshowthemostpromise.Both
betweengroups.31 sharethesamereceptorcomplexandhavebeenprovento
playacrucialroleinfibrosisandwoundhealing.65Reifen-
rath et al54 found that incorporation of TGF-b3 into an
DISCUSSION electrospunchitosan-coatedpolycaprolactonefiberscaffold
ledtobiomechanicalmaximumforcevaluesthatweresim-
The results of this review indicated that preclinically, a ilar to those of the native tendon (P (cid:2) .01). Surprisingly,
large variety of substances have been investigated, the Reifenrath et al54 found no improved histological findings
majorityofwhichledtoimprovedrepairconstructs.Nota- with the biomechanical improvements. This is in contrast
bly, ADSCs, BMSCs, and growth factors including TGF-b tothefindingsofHanetal21ofimprovedhistologywithno
and FGF had positive effects. PRP and ADSCs have been biochemical improvements when delivered in tendon-
researched in the clinical setting with various technique specific cross-linked gelatin. This highlights the impor-
improvementsleadingtoimprovedpatientoutcomes. tance of testing not only various biologic injectable
The MIBO guidelines were published to decrease compounds,butalsothevehicleactivecompounddelivery.
unknownheterogeneityofcompositionsinorthopaedicclin- Withfurtheradvancesinbiomaterials,suchasutilization
ical studies utilizing PRP and mesenchymal stem cells.37 ofnanocarrierstodeliverTGF-b,theexpansionofdelivery
Clinical studies included in this systematic review were methods shows promise in advancing preclinical develop-
found to, on average, follow 66% of the relevant MIBO mentofgrowthfactordelivery.33
reporting guidelines. Most commonly absent were the While significant heterogeneity exists in the literature
details of the exact PRP composition injected. This likely regarding PRP with multiple trials failing to demonstrate
wasbecauseofintraoperativePRPharvestingandproces- anysignificantimprovementinclinicalorradiographicout-
singinmanytrials.FurtheradherencetoMIBOguidelines comes,arecentadvancementinthepreclinicalsettingthat
inthefuturemayleadtoimprovedidentificationofspecific may spark intrigue is the role of ozone augmentation of
variables that improve outcomes. Preclinically, no such PRP injections in RCR. Gurger et al19 showed that ozone
reportingguidelineshaveyetbeendeveloped. therapy has been investigated in many acute and chronic

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 11
tendinopathiesbuthasyettobeinvestigatedinRCR.Ithas for RCR. Further work is warranted in determining opti-
been found to increase the release of various platelet mal methods of delivery of ADSCs, as initial results show
growth factors from PRP including PDGF, TGF-b1, and potentialtoimprovepatientoutcomes.
IL-8. Gurger et al found that the combination of PRP and
ozoneleadtohistopathologythatresembledahealthyrab-
Limitations
bit; additionally, it resulted in the highest biomechanical
findings.
Whileourreviewwascomprehensiveuponinjectablesstud-
Furthermore,deliveryofPRPmayplayanessentialrole.
ied for repair, select injectables that do not have strong
Both improving PRP preparation and utilizing various
evidenceinvestigatingRCRsbuthavebeenshowntoaffect
modes of PRP delivery such as fibrin gels show potential
the supraspinatus tendon were excluded from our review
in improving RCR biologic injectable augmentation and
namely for lack of 2-year follow-up or combination proto-
shouldbe furtherexplored as methods to enhance patient
cols; however, they may still warrant attention. Addition-
outcomes. In 1 study, a concentrated PRP globule with
ally,thereislargevariabilityinthepreparationandsource
fibrin matrix was shuttled over a suture in an attempt to
of injectable biologics coupled with a small sample size of
maintain concentrated PRP at the repair site over time.
clinical studies that may contribute to result heterogene-
Therewasastatisticallysignificantdecreaseinretearsin
ity.61 Regarding randomized controlled trials of PRP, a
thePRPgroup(30%vs60%inthecontrolgroup;P¼.03)as recent meta-analysis performed by Parisien et al50 found
seenonMRIevaluation.2Walshetal67preparedleukocyte-
that the majority of PRP in RCR randomized controlled
poorPRPthroughdoublecentrifugationfollowedbytheuse
trialshadafragilityindexof4.Thisimpliesthatreversal
ofcalciumchlorideforactivation.Randellietal52,53demon-
of only a small amount of patient outcomes is significant
stratedthatPRPadministration utilizingdoublecentrifu-
enough to alter trial significance. As suggested, future
gation and activation with calcium chloride may lead to
trials reporting a fragility index and fragility quotient in
increases in ASES and SANE scores at a 10-year follow-
additiontothePvaluemayleadtoaclearerpictureofPRP
up.BoththemethodofPRPpreparationandgrowthfactors
effectiveness in RCR. Despite this relatively limited evi-
within the PRP being released over a longer time period
dence,RCRaugmentationwithinjectablebiologicsremains
(approximately 30 days) likely contributed to the lower
apromisingavenueofimprovingpatientoutcomes.
retear rate. Other methods such as sonication, light, and
electrical activation should also be investigated to further
enhancetheplatelets’anabolicproperties.11Beyondutiliz-
CONCLUSION
ingoptimalpreparationmethods,newbiomaterialvehicles
of delivery are being developed, such as low-molecular-
Preclinically, a wide range of injectables have been inves-
weight fucoidan-functionalized poly(ester-urea-urethane)
tigated,withapproximately83%ofstudiesdemonstrating
scaffolds,whichmayimprovebioactivationofbothPRPand
apositivebiomechanicalorhistologicaleffectandnostud-
thesurroundingnativetissue.56Additionally,tearsizemay
ies showing an overall negative effect. Clinically, while
alsoplayaroleindecidingwhethertoaugmentrepairwith
thereremainscantdataatlong-termfollow-upinfavorof
PRP, as Randelli et al52 found that only low-grade tears
PRP, utilization of innovative delivery techniques may
that did not fully retract to the glenoid articular surface
reduce the risk of arthroscopic washout of PRP and has
benefited from PRP injection at the 2-year mark. Utiliza-
been shown to potentially improve retear rates. Further,
tionoftheseinnovativedeliverytechniquesmayreducethe
ADSCs have been shown to reduce retear rates at a
riskofarthroscopicwashoutofPRPandhasbeenshownto
28-monthfollow-up.
potentiallyimproveretearrates.
BMSCs and ADSCs have demonstrated an overall posi-
tiveeffectinthepreclinicalsetting.Increasedultimateload
REFERENCES
to failure and improved histological findings, such as
increased fibrocartilage quantity and quality, were found
1. Arimura H, Shukunami C, Tokunaga T, et al. TGF-beta1 improves
inbothBMSCsandADSCs.BMSCshaveshownbenefitnot
biomechanicalstrengthbyextracellularmatrixaccumulationwithout
onlyintheshort-termrecoveryperiod,butalsointhelong increasingthenumberoftenogeniclineagecellsinaratrotatorcuff
term. Hernigou et al23 found that at a 10-year follow-up, repairmodel.AmJSportsMed.2017;45(10):2394-2404.doi:10.1177/
87% of the BMSC augmentation group had intact rotator 0363546517707940
cuffs,whereasonly44%inthecontrolgroupdid.Regarding 2. BarberFA,HrnackSA,SnyderSJ,HapaO.Rotatorcuffrepairhealing
influencedbyplatelet-richplasmaconstructaugmentation.Arthros-
translation to clinical practice, ADSCs are easier to har-
copy.2011;27(8):1029-1035.doi:10.1016/j.arthro.2011.06.010
vest,mayprovidefewercomplications,andpossesshigher
3. BuchmannS,SandmannGH,WalzL,etal.Growthfactorreleaseby
MSCproliferativecapacity27;however,BMSCshavehigher vesicularphospholipidgels:in-vitroresultsandapplicationforrotator
chondrogenic capacity. ADSCs are thought to upregulate cuffrepairinaratmodel.BMCMusculoskeletDisord.2015;16:82.doi:
tendon-relatedgenesthroughimmunemodulationanddif- 10.1186/s12891-015-0542-1
ferentiation.64Furthermore,amatched-cohortstudydem- 4. ChaeSW,KangJY,LeeJ,HanSH,KimSY.Effectofstructuraldesign
on the pullout strength of suture anchors for rotator cuff repair. J
onstratedthattheretearratewassignificantlylowerinthe
OrthopRes.2018;36(12):3318-3327.doi:10.1002/jor.24135
ADSC-augmentedgroup(14.3%)thaninthecontrolrepair
5. DayMA,WestermannRW,BedardNA,GlassNA,WolfBR.Trends
group (28.5%) at a 28-month follow-up (P < .001).31 The associatedwithopenversusarthroscopicrotatorcuffrepair.HSSJ.
combinationmakesADSCsapromisinginjectableaugment 2019;15(2):133-136.doi:10.1007/s11420-018-9628-2

NEW PAGE

12 Bonoetal TheOrthopaedicJournalofSportsMedicine
6. DegenRM,CarboneA,CarballoC,etal.Theeffectofpurifiedhuman controlled study. Int Orthop. 2014;38(9):1811-1818. doi:10.1007/
bonemarrow-derivedmesenchymalstemcellsonrotatorcufftendon s00264-014-2391-1
healinginanathymicrat.Arthroscopy.2016;32(12):2435-2443.doi: 24. HigginsJP,AltmanDG,GotzschePC,etal.TheCochraneCollabora-
10.1016/j.arthro.2016.04.019 tion’stoolforassessingriskofbiasinrandomisedtrials.BMJ.2011;
7. DuchmanKR,GoetzJE,UribeBU,etal.Delayedadministrationof 343:d5928.doi:10.1136/bmj.d5928
recombinanthumanparathyroidhormoneimprovesearlybiomechan- 25. HondaH,GotohM,KanazawaT,etal.Hyaluronicacidaccelerates
icalstrengthinaratrotatorcuffrepairmodel.JShoulderElbowSurg. tendon-to-bonehealing afterrotatorcuffrepair.AmJSportsMed.
2016;25(8):1280-1287.doi:10.1016/j.jse.2015.12.016 2017;45(14):3322-3330.doi:10.1177/0363546517720199
8. DukanR,BommierA,RousseauMA,BoyerP.Arthroscopicknotless 26. IannottiJP,DeutschA,GreenA,etal.Timetofailureafterrotatorcuff
tapebridging with autologous platelet-rich fibrin gel augmentation: repair: a prospective imaging study. J Bone Joint Surg Am. 2013;
functional and structural results. Phys Sportsmed. 2019;47(4): 95(11):965-971.doi:10.2106/JBJS.L.00708
455-462.doi:10.1080/00913847.2019.1623994 27. KernS,EichlerH,StoeveJ,KluterH,BiebackK.Comparativeanal-
9. Dyrna F, Zakko P, Pauzenberger L, McCarthy MB, Mazzocca AD, ysisof mesenchymalstem cells frombonemarrow, umbilical cord
Dyment NA. Human subacromial bursal cells display superior blood,oradiposetissue.StemCells.2006;24(5):1294-1301.doi:10.
engraftment versus bone marrow stromal cells in murine tendon 1634/stemcells.2005-0342
repair. Am J Sports Med. 2018;46(14):3511-3520. doi:10.1177/ 28. KimHM,CaldwellJM,BuzaJA,etal.Factorsaffectingsatisfaction
0363546518802842 andshoulderfunctioninpatientswitharecurrentrotatorcufftear.J
10. EppleyBL,WoodellJE,HigginsJ.Plateletquantificationandgrowth BoneJointSurgAm.2014;96(2):106-112.doi:10.2106/JBJS.L.01649
factoranalysisfromplatelet-richplasma:implicationsforwoundheal- 29. KimJO,LeeJH,KimKS,JiJH,KohSJ,LeeJH.Rotatorcuffbridging
ing.PlastReconstrSurg.2004;114(6):1502-1508.doi:10.1097/01.prs. repairusingacellulardermalmatrixinlargetomassiverotatorcuff
0000138251.07040.51 tears:histologicandclinicalanalysis.JShoulderElbowSurg.2017;
11. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich 26(11):1897-1907.doi:10.1016/j.jse.2017.04.010
plasma: new performanceunderstandings and therapeutic consid- 30. KimYS,KimSE,BaeSH,LeeHJ,JeeWH,ParkCK.Tearprogression
erations in 2020. Int J Mol Sci. 2020;21(20):7794. doi:10.3390/ ofsymptomaticfull-thicknessandpartial-thicknessrotatorcufftears
ijms21207794 asmeasuredbyrepeatedMRI.KneeSurgSportsTraumatolArthrosc.
12. FluryM,RickenbacherD,SchwyzerHK,etal.Doespureplatelet-rich 2017;25(7):2073-2080.doi:10.1007/s00167-016-4388-3
plasmaaffectpostoperativeclinicaloutcomesafterarthroscopicrota- 31. KimYS,SungCH,ChungSH,KwakSJ,KohYG.Doesaninjectionof
torcuffrepair?Arandomizedcontrolledtrial.AmJSportsMed.2016; adipose-derivedmesenchymalstemcellsloadedinfibringlueinflu-
44(8):2136-2146.doi:10.1177/0363546516645518 encerotatorcuffrepairoutcomes?Aclinicalandmagneticresonance
13. FuX,LiuG,HalimA,JuY,LuoQ,SongAG.Mesenchymalstemcell imagingstudy.AmJSportsMed.2017;45(9):2010-2018.doi:10.1177/
migration and tissue repair. Cells. 2019;8(8):784. doi:10.3390/ 0363546517702863
cells8080784 32. KubrovaE,D’SouzaRS,HuntCL,WangQ,vanWijnenAJ,QuW.
14. GalatzLM,BallCM,TeefeySA,MiddletonWD,YamaguchiK.The Injectablebiologics:whatistheevidence?AmJPhysMedRehabil.
outcomeandrepairintegrityofcompletelyarthroscopicallyrepaired 2020;99(10):950-960.doi:10.1097/PHM.0000000000001407
large and massive rotatorcuff tears.J Bone Joint Surg Am. 2004; 33. KwakEA,LeeNY.SynergeticrolesofTGF-betasignalingintissue
86(2):219-224.doi:10.2106/00004623-200402000-00002 engineering. Cytokine. 2019;115:60-63. doi:10.1016/j.cyto.2018.12.
15. GilotraMN,ShorofskyMJ,SteinJA,MurthiAM.Healingofrotatorcuff 010
tendonsusingbotulinumtoxinAandimmobilizationinaratmodel. 34. KwonDR,ParkGY,LeeSC.Treatmentoffull-thicknessrotatorcuff
BMC Musculoskelet Disord. 2016;17:127. doi:10.1186/s12891-016- tendontearusingumbilicalcordblood-derivedmesenchymalstem
0978-y cellsandpolydeoxyribonucleotidesinarabbitmodel.StemCellsInt.
16. GordonNM,MaxsonS,HoffmanJK.Biologicallyenhancedhealingof 2018;2018:7146384.doi:10.1155/2018/7146384
the rotator cuff. Orthopedics. 2012;35(6):498-504. doi:10.3928/ 35. KwonJ,KimYH,RheeSM,etal.Effectsofallogenicdermalfibro-
01477447-20120525-06 blastsonrotatorcuffhealinginarabbitmodelofchronictear.AmJ
17. Gu¨lec¸yu¨zMF,MachaK,PietschmannMF,etal.Allogenicmyocytes SportsMed.2018;46(8):1901-1908.doi:10.1177/0363546518770428
and mesenchymal stem cells partially improve fatty rotator cuff 36. Lafosse L, Brzoska R, Toussaint B, Gobezie R.The outcome and
degeneration in a rat model. Stem Cell Rev Rep. 2018;14(6): structuralintegrityofarthroscopicrotatorcuffrepairwithuseofthe
847-859.doi:10.1007/s12015-018-9829-6 double-row suture anchor technique. Surgical technique. J Bone
18. GumucioJP,FloodMD,RocheSM,etal.Stromalvascularstemcell JointSurgAm.2008;90(suppl2pt2):275-286.doi:10.2106/JBJS.H.
treatment decreases muscle fibrosis following chronic rotator cuff 00388
tear.IntOrthop.2016;40(4):759-764.doi:10.1007/s00264-015-2937- 37. LamplotJD,RodeoSA,BrophyRH.Apracticalguideforthecurrent
x useofbiologictherapiesinsportsmedicine.AmJSportsMed.2020;
19. Gurger M, Once G, Yilmaz E, et al. The effect of the platelet-rich 48(2):488-503.doi:10.1177/0363546519836090
plasmaandozonetherapyontendon-to-bonehealingintherabbit 38. LiuB,JeongHJ,YeoJH,OhJH.Efficacyofintraoperativeplatelet-
rotatorcuffrepairmodel.JOrthopSurgRes.2021;16(1):202.doi:10. rich plasma augmentation and postoperative platelet-rich plasma
1186/s13018-021-02320-w booster injection for rotator cuff healing: a randomized controlled
20. GwinnerC,GerhardtC,HaneveldH,ScheibelM.Two-stagedappli- clinical trial. Orthop J Sports Med. 2021;9(6):23259671211006100.
cationofPRPinarthroscopicrotatorcuffrepair:amatched-pairanal- doi:10.1177/23259671211006100
ysis.ArchOrthopTraumaSurg.2016;136(8):1165-1171.doi:10.1007/ 39. LiuXN,YangCJ,KimJE,etal.Enhancedtendon-to-bonehealingof
s00402-016-2499-4 chronicrotatorcufftearsbybonemarrowaspirateconcentrateina
21. HanB,JonesIA,YangZ,FangW,VangsnessCTJr.Repairofrotator rabbitmodel.ClinOrthopSurg.2018;10(1):99-110.doi:10.4055/cios.
cufftendondefectsinagedratsusingagrowthfactorinjectablegel 2018.10.1.99
scaffold.Arthroscopy.2020;36(3):629-637.doi:10.1016/j.arthro.2019. 40. LuLY, KuangCY, YinF.Magnetic resonance imaging andbiome-
09.015 chanicalanalysisofadipose-derivedstromalvascularfractionapplied
22. HaradaY,MifuneY,InuiA,etal.Rotatorcuffrepairusingcellsheets onrotatorcuffrepairinrabbits.ChinMedJ(Engl).2018;131(1):69-74.
derivedfromhumanrotatorcuffinaratmodel.JOrthopRes.2017; doi:10.4103/0366-6999.221264
35(2):289-296.doi:10.1002/jor.23289 41. LuLY,MaM,CaiJF,etal.Effectsoflocalapplicationofadipose-
23. HernigouP,FlouzatLachanietteCH,DelambreJ,etal.Biologicaug- derivedstromalvascularfractionontendon-bonehealingafterrotator
mentationofrotatorcuffrepairwithmesenchymalstemcellsduring cufftearinrabbits.ChinMedJ(Engl).2018;131(21):2620-2622.doi:
arthroscopy improves healing and prevents further tears: a case- 10.4103/0366-6999.244120

NEW PAGE

TheOrthopaedicJournalofSportsMedicine EvidenceforUtilizationofInjectableBiologicAugmentation 13
42. MalavoltaEA,GracitelliMEC,AssuncaoJH,FerreiraNetoAA,Bor- 57. Rothrauff BB, Smith CA, Ferrer GA, et al. The effect of adipose-
dalo-Rodrigues M,de CamargoOP. Clinical andstructural evalua- derived stem cells on enthesis healing after repair of acute and
tionsofrotatorcuffrepairwithandwithoutaddedplatelet-richplasma chronic massive rotator cuff tears in rats. J Shoulder Elbow Surg.
at 5-year follow-up:aprospective randomized study.AmJSports 2019;28(4):654-664.doi:10.1016/j.jse.2018.08.044
Med.2018;46(13):3134-3141.doi:10.1177/0363546518795895 58. Ruiz-Alonso S, Lafuente-Merchan M, Ciriza J, Saenz-Del-Burgo L,
43. MarquesLF,StessukT,CamargoIC,SabehJuniorN,dosSantosL, PedrazJL.Tendontissueengineering:cells,growthfactors,scaffolds
Ribeiro-PaesJT.Platelet-richplasma(PRP):methodologicalaspects and production techniques. J Control Release. 2021;333:448-486.
andclinicalapplications.Platelets.2015;26(2):101-113.doi:10.3109/ doi:10.1016/j.jconrel.2021.03.040
09537104.2014.881991 59. SongW,MaZ,WangC,LiH,HeY.Pro-chondrogenicandimmuno-
44. MatthewsTJ,HandGC,ReesJL,AthanasouNA,CarrAJ.Pathology modulatorymelatonin-loadedelectrospunmembranesfortendon-to-
ofthetornrotatorcufftendon.Reductioninpotentialforrepairastear bonehealing.JMaterChemB.2019;7(42):6564-6575.doi:10.1039/
size increases. J Bone Joint Surg Br. 2006;88(4):489-495. doi:10. c9tb01516g
1302/0301-620X.88B4.16845
60. TokunagaT,KarasugiT,ArimuraH,etal.Enhancementofrotatorcuff
45. MillerBS,DownieBK,KohenRB,etal.Whendorotatorcuffrepairs
tendon-bonehealingwithfibroblastgrowthfactor2impregnatedin
fail?Serialultrasoundexaminationafterarthroscopicrepairoflarge
gelatin hydrogel sheets in a rabbit model. J Shoulder ElbowSurg.
and massive rotator cuff tears. Am J Sports Med. 2011;39(10):
2017;26(10):1708-1717.doi:10.1016/j.jse.2017.03.020
2064-2070.doi:10.1177/0363546511413372
61. TschonM,FiniM,GiardinoR,etal.Lightsandshadowsconcerning
46. MoherD,LiberatiA,TetzlaffJ,AltmanDG,GroupP.PreferredReport-
plateletproductsformusculoskeletalregeneration.FrontBiosci(Elite
ingItemsforSystematicReviewsandMeta-Analyses:thePRISMA
Ed).2011;3(1):96-107.doi:10.2741/e224
statement.AnnInternMed.2009;151(4):264-269,W64.doi:10.7326/
62. TudiscoC,BisicchiaS,SavareseE,etal.Single-rowvs.double-row
0003-4819-151-4-200908180-00135
arthroscopicrotatorcuffrepair:clinicaland3TeslaMRarthrography
47. NussCA,HuegelJ,Boorman-PadgettJF,etal.Poly-N-acetylglucos-
results. BMC Musculoskelet Disord. 2013;14:43. doi:10.1186/1471-
amine (sNAG) enhances early rotator cuff tendon healing in a rat
2474-14-43
model. Ann Biomed Eng. 2017;45(12):2826-2836. doi:10.1007/
63. USFoodandDrugAdministration.Frameworkfortheregulationof
s10439-017-1923-4
regenerativemedicineproducts.May21,2019.AccessedJanuary6,
48. OztermeliA,KaracaS,YucelI,MidiA,SenEI,OzturkBY.Theeffectof
2023. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-
erythropoietinonratrotatorcuffrepairmodel:anexperimentalstudy.
JOrthopSurg(HongKong).2019;27(2):2309499019856389.doi:10. therapy-products/framework-regulation-regenerative-medicine-
1177/2309499019856389 products
49. Pandey V, Bandi A, Madi S, et al. Does application of moderately 64. UsuelliFG,D’AmbrosiR,MaccarioC,IndinoC,ManziL,MaffulliN.
concentratedplatelet-richplasmaimproveclinicalandstructuralout- Adipose-derivedstemcellsinorthopaedicpathologies.BrMedBull.
comeafterarthroscopicrepairofmedium-sizedtolargerotatorcuff 2017;124(1):31-54.doi:10.1093/bmb/ldx030
tear? A randomized controlled trial.J Shoulder Elbow Surg. 2016; 65. VanderArkA,CaoJ,LiX.TGF-betareceptors:inandbeyondTGF-
25(8):1312-1322.doi:10.1016/j.jse.2016.01.036 beta signaling. Cell Signal. 2018;52:112-120. doi:10.1016/j.cellsig.
50. ParisienRL,EhlersC,CusanoA,TornettaPIII,LiX,WangD.The 2018.09.002
statistical fragility of platelet-rich plasma in rotator cuff surgery: a 66. VastamakiM,LohmanM,BorgmastarsN.Rotatorcuffintegritycor-
systematic review and meta-analysis. Am J Sports Med. 2021; relateswithclinicalandfunctionalresultsataminimum16yearsafter
49(12):3437-3442.doi:10.1177/0363546521989976 open repair. Clin Orthop Relat Res. 2013;471(2):554-561. doi:10.
51. PonceBA,HosemannCD,RaghavaP,TateJP,SheppardED,Eber- 1007/s11999-012-2494-1
hardt AW. A biomechanical analysis of controllable intraoperative 67. WalshMR,NelsonBJ,BramanJP,etal.Platelet-richplasmainfibrin
variablesaffectingthestrengthofrotatorcuffrepairsatthesuture- matrixtoaugmentrotatorcuffrepair:aprospective,single-blinded,
tendoninterface.AmJSportsMed.2013;41(10):2256-2261.doi:10. randomized study with 2-year follow-up. J Shoulder Elbow Surg.
1177/0363546513499228 2018;27(9):1553-1563.doi:10.1016/j.jse.2018.05.003
52. RandelliP,ArrigoniP,RagoneV,AliprandiA,CabitzaP.Plateletrich 68. Wang C, Hu Q, Song W, Yu W, He Y. Adipose stem cell-derived
plasmainarthroscopicrotatorcuffrepair:aprospectiveRCTstudy,2- exosomesdecreasefattyinfiltrationandenhancerotatorcuffhealing
yearfollow-up.JShoulderElbowSurg.2011;20(4):518-528.doi:10. in a rabbit model of chronic tears. Am J Sports Med. 2020;48(6):
1016/j.jse.2011.02.008 1456-1464.doi:10.1177/0363546520908847
53. Randelli PS, Stoppani CA, Santarsiero G, Nocerino E, Menon A. 69. Wang C, Song W, Chen B, Liu X, He Y. Exosomes isolated from
Platelet-rich plasma in arthroscopic rotator cuff repair: clinical and adipose-derivedstemcells:anewcell-freeapproachtopreventthe
radiologicalresultsofaprospectiverandomizedcontrolledtrialstudy muscledegenerationassociatedwithtornrotatorcuffs.AmJSports
at 10-year follow-up. Arthroscopy. 2022;38(1):51-61. doi:10.1016/j. Med.2019;47(13):3247-3255.doi:10.1177/0363546519876323
arthro.2021.05.017 70. WangD,TanH,LebaschiAH,etal.Kartogeninenhancescollagen
54. ReifenrathJ,WellmannM,KempfertM,etal.TGF-beta3loadedelec-
organization andmechanical strengthof therepaired enthesis in a
trospunpolycaprolactonfibrescaffoldsforrotatorcufftearrepair:an
murine model of rotator cuff repair. Arthroscopy. 2018;34(9):
in vivo study in rats. Int J Mol Sci. 2020;21(3):1046. doi:10.3390/
2579-2587.doi:10.1016/j.arthro.2018.04.022
ijms21031046
71. WellsGA,SheaB,O’ConnellD,etal.TheNewcastle-OttawaScale
55. Rhee SM, Kim YH, Park JH, et al. Allogeneic dermal fibroblasts
(NOS)forassessingthequalityofnonrandomisedstudiesinmeta-
improvetendon-to-bonehealinginarabbitmodelofchronicrotator
analyses.OttawaHospitalResearchInstitute.AccessedJanuary6,
cuff tear compared with platelet-rich plasma. Arthroscopy. 2022;
2023. https://www.ohri.ca//programs/clinical_epidemiology/oxford.
38(7):2118-2128.doi:10.1016/j.arthro.2021.12.029
asp
56. Rohman G, Langueh C, Ramtani S, et al. The use of platelet-rich
72. Yonemitsu R, Tokunaga T, Shukunami C, et al. Fibroblast growth
plasma to promote cell recruitment into low-molecular-weight
factor2enhancestendon-to-bonehealinginaratrotatorcuffrepair
fucoidan-functionalizedpoly(ester-urea-urethane)scaffoldsforsoft-
of chronic tears. Am J Sports Med. 2019;47(7):1701-1712. doi:10.
tissue engineering. Polymers (Basel). 2019;11(6):1016. doi:10.3390/
1177/0363546519836959
polym11061016

NEW PAGE

14 Bonoetal TheOrthopaedicJournalofSportsMedicine
APPENDIX
TABLEA1
Newcastle-OttawaScaleQualityAssessmentforNonrandomizedStudiesa
FirstAuthor(Year) Selection Comparability Outcome Total AHRQStandard
Gwinner(2016)20 4 1 3 8 Goodquality
Dukan(2019)8 4 1 2 7 Goodquality
Barber(2011)2 4 1 2 8 Goodquality
Kim(2017)31 4 1 3 8 Goodquality
aAHRQ,AgencyforHealthcareResearchandQuality.
TABLEA2
CochraneRisk-of-BiasToolforRandomizedControlledTrialsa
CochraneRisk-of-BiasItemb
FirstAuthor(Year) 1 2 3 4 5 6 7 AHRQStandard
Malavolta(2018)42 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Walsh(2018)67 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Flury(2016)12 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Pandey(2016)49 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Randelli(2011)52 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Randelli(2022)53 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
Liu(2021)38 Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Lowrisk Goodquality
aAHRQ,AgencyforHealthcareResearchandQuality.
bItems:1¼randomsequencegeneration;2¼allocationconcealment;3¼selectivereporting;4¼blindingofparticipantsandpersonnel;
5¼blindingofoutcomeassessment;6¼incompleteoutcomedata;7¼otherbias.

NEW PAGE